Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulated Status of its CRISPR Genome-Edited C3007 Trait in C...
August 17 2020 - 8:30AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience
company, today announced that it has obtained a positive response
from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its
CRISPR genome-edited trait C3007 in canola plant lines developed
for increased oil content. Yield10’s submission along with
the USDA-APHIS BRS response is posted on the USDA’s
website.
In June 2020, Yield10 submitted an “Am I regulated?” letter to
the BRS, requesting confirmation of the regulatory status for
canola plant lines containing the Company’s novel, CRISPR
genome-edited C3007 trait. The positive USDA-APHIS response came in
the form of a published letter indicating that the plant lines do
not meet the definition of a regulated article under 7 CFR Part 340
regulations. Confirmation of the regulatory status of the plants
will enable Yield10 to conduct field tests of CRISPR genome-edited
canola plants in the United States in the 2021 growing season.
“Our team successfully engineered CRISPR genome-edited versions
of C3007 in canola and now clarified their regulatory status
through USDA-APHIS, marking major milestones in our development
program to produce new varieties of canola with higher oil
content,” said Kristi Snell, Ph.D., Chief Science Officer of
Yield10 Bioscience. “With the deployment of the C3007 trait in
canola as an oil boosting trait, we have expanded the portfolio of
traits we are developing targeted towards increasing the
performance of canola. We are also developing and/or testing the
novel traits C3003 and C3004 to increase seed yield in canola. Each
of these traits represents different strategies to boost yield in
this important North American crop.”
“Yield10 is emerging as a technology leader in the development
of advanced technology to increase seed yield and oil content in
oilseed crops,” said Dr. Oliver Peoples, Chief Executive Officer of
Yield10 Bioscience. “We believe there is considerable potential for
C3007 and other trait gene technologies we are developing to
enhance oil biosynthesis and sustainably increase the production of
plant-based nutritional oils.”
In 2018, Yield10 licensed C3007 from the University of Missouri
(“MU”). The protein encoded by C3007, also known as BADC, is a
novel, negative regulator of the enzyme acetyl-CoA carboxylase
(ACCase), the key enzyme for producing fatty acids for oil
biosynthesis. In pilot studies conducted by MU researchers,
reducing activity of the protein encoded by C3007 resulted in
significantly increased oil content in seeds. Yield10
researchers have successfully used CRISPR to inactivate one or more
copies of C3007 in Camelina and have seen evidence of increased oil
content in some lines evaluated in laboratory studies. Yield10
researchers believe that C3007 also has the potential to boost oil
content in canola. The use of CRISPR may enable an expedited
timeline for development and commercialization within the U.S.
market based on obtaining confirmation that USDA-APHIS does not
consider the lines to be regulated pursuant to 7 CFR part 340. The
lines may still be subject to regulation by EPA or FDA.
The CRISPR edited C3007 trait designed to increase oil content
could deliver significant economic value for the commercialization
of identity preserved, specialty oilseed crops. This is
particularly true where the key economic drivers are altered oil
compositions with improved nutritional profiles or oils which have
been modified for aquaculture feed or industrial markets. These
traits may also be used to increase production of edible oils in
major oilseed crops including soybean and canola.
About Yield10
Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
developing crop innovations for sustainable global food security.
The Company uses its “Trait Factory” including the “GRAIN” big data
mining trait gene discovery tool as well as the Camelina oilseed
“Fast Field Testing” system to develop high value seed traits for
the agriculture and food industries. As a path toward
commercialization of novel traits, Yield10 is pursuing a partnering
approach with major agricultural companies to drive new traits into
development for canola, soybean, corn, and other commercial crops.
The Company is also developing improved Camelina varieties as a
platform crop for the production and commercialization of
nutritional oils, proteins, and PHA biomaterials. The Company’s
expertise in oilseed crops extends into canola, where it is
currently field testing novel yield traits to generate trait
performance data to drive additional licensing opportunities.
Yield10 is headquartered in Woburn, MA and has an Oilseeds Center
of Excellence in Saskatoon, Canada.
For more information about the Company, please visit the website
and follow the Company on Twitter and
LinkedIn.
(YTEN-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, statements regarding the potential timing for
conducting field tests of CRISPR genome-edited C3007 canola plants
and for development and commercialization within the U.S. market,
the ability of C3007 to increase oil content in oilseed crops
and to deliver economic value in other areas, and the possibility
of using genome-editing technology to rapidly deploy desirable,
novel traits into commercial agricultural crops, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including the risks and uncertainties detailed in Yield10
Bioscience's filings with the Securities and Exchange Commission.
Yield10 assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
matters described herein.
Contacts:
Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2023 to Apr 2024